SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene ...
OKLAHOMA CITY – Deep discussions on important issues affecting Native American tribes will highlight the 38th Sovereignty Symposium, which is currently accepting panel presentation proposals and ...
The UAB Office of Service Learning and Undergraduate Research connects students, faculty, and community nonprofit partners to enrich student academic learning, promote civic engagement, and to ...
For more information about the event, please visit the meeting website. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of ...
A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel highlighted various alleged “safety uncertainties” of the mRNA COVID-19 ...
SEATTLE, Nov. 6, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, ...
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase ...
Startup professionals will have an opportunity to learn how to raise funds and better manage their finances. IMPACT 307, a University of Wyoming program, will host a Startup Lunch and Learn webinar ...
Nine bills passed by Democrats but stalled by Republican House Speaker Matt Hall at the start of the year's legislative session should be sent to Gov. Gretchen Whitmer's desk for signature, a Michigan ...
Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with ...
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma Poster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results